5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Monitor O
patients O
for O
suicidal O
behavior O
and O
ideation O
( O
5.1 O
) O
* O
VIMPAT O
may O
cause O
dizziness O
and O
ataxia O
( O
5.2 O
) O
* O
Cardiac O
Rhythm O
and O
Conduction O
Abnormalities O
: O
ECG O
before O
beginning O
VIMPAT O
, O
and O
after O
VIMPAT O
is O
titrated O
to O
steady-state O
maintenance O
dose O
is O
recommended O
in O
patients O
with O
known O
cardiac O
conduction O
problems O
, O
taking O
drugs O
known O
to O
induce O
PR O
interval O
prolongation O
, O
or O
with O
severe O
cardiac O
disease O
( O
5.3 O
) O
* O
VIMPAT O
may O
cause O
syncope O
( O
5.4 O
) O
* O
VIMPAT O
should O
be O
gradually O
withdrawn O
to O
minimize O
the O
potential O
of O
increased O
seizure O
frequency O
( O
5.5 O
) O
* O
Multiorgan O
Hypersensitivity O
Reactions O
( O
5.6 O
) O
5.1 O
Suicidal O
Behavior O
and O
Ideation O
Antiepileptic O
drugs O
( O
AEDs O
) O
, O
including O
VIMPAT O
, O
increase O
the O
risk O
of O
suicidal B-OSE_Labeled_AE
thoughts I-OSE_Labeled_AE
or O
behavior O
in O
patients O
taking O
these O
drugs O
for O
any O
indication O
. O

Patients O
treated O
with O
any O
AED O
for O
any O
indication O
should O
be O
monitored O
for O
the O
emergence O
or O
worsening B-NonOSE_AE
of I-NonOSE_AE
depression I-NonOSE_AE
, O
suicidal B-NonOSE_AE
thoughts I-NonOSE_AE
or O
behavior O
, O
and/or O
any O
unusual O
changes B-NonOSE_AE
in I-NonOSE_AE
mood I-NonOSE_AE
or O
behavior O
. O

Pooled O
analyses O
of O
199 O
placebo-controlled O
clinical O
trials O
( O
mono- O
and O
adjunctive O
therapy O
) O
of O
11 O
different O
AEDs O
showed O
that O
patients O
randomized O
to O
one O
of O
the O
AEDs O
had O
approximately O
twice O
the O
risk O
( O
adjusted O
Relative O
Risk O
1.8 O
, O
95 O
% O
CI:1.2 O
, O
2.7 O
) O
of O
suicidal B-OSE_Labeled_AE
thinking I-OSE_Labeled_AE
or O
behavior O
compared O
to O
patients O
randomized O
to O
placebo O
. O

In O
these O
trials O
, O
which O
had O
a O
median O
treatment O
duration O
of O
12 O
weeks O
, O
the O
estimated O
incidence O
of O
suicidal B-OSE_Labeled_AE
behavior I-OSE_Labeled_AE
or O
ideation O
among O
27,863 O
AED-treated O
patients O
was O
0.43 O
% O
, O
compared O
to O
0.24 O
% O
among O
16,029 O
placebo-treated O
patients O
, O
representing O
an O
increase O
of O
approximately O
one O
case O
of O
suicidal B-OSE_Labeled_AE
thinking I-OSE_Labeled_AE
or O
behavior O
for O
every O
530 O
patients O
treated O
. O

There O
were O
four O
suicides B-OSE_Labeled_AE
in O
drug-treated O
patients O
in O
the O
trials O
and O
none O
in O
placebo-treated O
patients O
, O
but O
the O
number O
of O
events O
is O
too O
small O
to O
allow O
any O
conclusion O
about O
drug O
effect O
on O
suicide B-NonOSE_AE
. O

The O
increased O
risk O
of O
suicidal B-OSE_Labeled_AE
thoughts I-OSE_Labeled_AE
or O
behavior O
with O
AEDs O
was O
observed O
as O
early O
as O
one O
week O
after O
starting O
treatment O
with O
AEDs O
and O
persisted O
for O
the O
duration O
of O
treatment O
assessed O
. O

Because O
most O
trials O
included O
in O
the O
analysis O
did O
not O
extend O
beyond O
24 O
weeks O
, O
the O
risk O
of O
suicidal B-NonOSE_AE
thoughts I-NonOSE_AE
or O
behavior O
beyond O
24 O
weeks O
could O
not O
be O
assessed O
. O

The O
risk O
of O
suicidal B-NonOSE_AE
thoughts I-NonOSE_AE
or O
behavior O
was O
generally O
consistent O
among O
drugs O
in O
the O
data O
analyzed O
. O

The O
finding O
of O
increased O
risk O
with O
AEDs O
of O
varying O
mechanisms O
of O
action O
and O
across O
a O
range O
of O
indications O
suggests O
that O
the O
risk O
applies O
to O
all O
AEDs O
used O
for O
any O
indication O
. O

The O
risk O
did O
not O
vary O
substantially O
by O
age O
( O
5-100 O
years O
) O
in O
the O
clinical O
trials O
analyzed O
. O

Table O
1 O
shows O
absolute O
and O
relative O
risk O
by O
indication O
for O
all O
evaluated O
AEDs O
. O

Table O
1 O
Risk O
by O
Indication O
for O
Antiepileptic O
Drugs O
in O
the O
Pooled O
Analysis O
Indication O
Placebo O
Patients O
with O
Events O
Per O
1000 O
Patients O
Drug O
Patients O
with O
Events O
Per O
1000 O
Patients O
Relative O
Risk O
: O
Incidence O
of O
Events O
in O
Drug O
Patients/Incidence O
in O
Placebo O
Patients O
Risk O
Difference O
: O
Additional O
Drug O
Patients O
with O
Events O
Per O
1000 O
Patients O
Epilepsy B-Not_AE_Candidate
1.0 O
3.4 O
3.5 O
2.4 O
Psychiatric B-Not_AE_Candidate
5.7 O
8.5 O
1.5 O
2.9 O
Other O
1.0 O
1.8 O
1.9 O
0.9 O
Total O
2.4 O
4.3 O
1.8 O
1.9 O
The O
relative O
risk O
for O
suicidal B-OSE_Labeled_AE
thoughts O
or O
behavior I-OSE_Labeled_AE
was O
higher O
in O
clinical O
trials O
for O
epilepsy B-Not_AE_Candidate
than O
in O
clinical O
trials O
for O
psychiatric B-Not_AE_Candidate
or O
other O
conditions O
, O
but O
the O
absolute O
risk O
differences O
were O
similar O
. O

Anyone O
considering O
prescribing O
VIMPAT O
or O
any O
other O
AED O
must O
balance O
this O
risk O
with O
the O
risk O
of O
untreated O
illness O
. O

Epilepsy B-Not_AE_Candidate
and O
many O
other O
illnesses O
for O
which O
antiepileptics O
are O
prescribed O
are O
themselves O
associated O
with O
morbidity O
and O
mortality O
and O
an O
increased O
risk O
of O
suicidal B-NonOSE_AE
thoughts I-NonOSE_AE
and O
behavior O
. O

Should O
suicidal B-NonOSE_AE
thoughts I-NonOSE_AE
and O
behavior O
emerge O
during O
treatment O
, O
the O
prescriber O
needs O
to O
consider O
whether O
the O
emergence O
of O
these O
symptoms O
in O
any O
given O
patient O
may O
be O
related O
to O
the O
illness O
being O
treated O
. O

Patients O
, O
their O
caregivers O
, O
and O
families O
should O
be O
informed O
that O
AEDs O
increase O
the O
risk O
of O
suicidal B-NonOSE_AE
thoughts I-NonOSE_AE
and O
behavior O
and O
should O
be O
advised O
of O
the O
need O
to O
be O
alert O
for O
the O
emergence O
or O
worsening O
of O
the O
signs O
and O
symptoms O
of O
depression B-NonOSE_AE
, O
any O
unusual O
changes B-NonOSE_AE
in I-NonOSE_AE
mood I-NonOSE_AE
or O
behavior O
, O
or O
the O
emergence O
of O
suicidal B-NonOSE_AE
thoughts I-NonOSE_AE
, O
behavior O
, O
or O
thoughts B-NonOSE_AE
about I-NonOSE_AE
self I-NonOSE_AE
- I-NonOSE_AE
harm I-NonOSE_AE
. O

Behaviors B-NonOSE_AE
of I-NonOSE_AE
concern I-NonOSE_AE
should O
be O
reported O
immediately O
to O
healthcare O
providers O
. O

5.2 O
Dizziness O
and O
Ataxia O
VIMPAT O
may O
cause O
dizziness B-OSE_Labeled_AE
and O
ataxia B-OSE_Labeled_AE
. O

In O
patients O
with O
partial B-Not_AE_Candidate
-onset O
seizures I-Not_AE_Candidate
taking O
1 O
to O
3 O
concomitant O
AEDs O
, O
dizziness B-OSE_Labeled_AE
was O
experienced O
by O
25 O
% O
of O
patients O
randomized O
to O
the O
recommended O
doses O
( O
200 O
to O
400 O
mg/day O
) O
of O
VIMPAT O
( O
compared O
with O
8 O
% O
of O
placebo O
patients O
) O
and O
was O
the O
adverse O
event O
most O
frequently O
leading O
to O
discontinuation O
( O
3 O
% O
) O
. O

Ataxia B-OSE_Labeled_AE
was O
experienced O
by O
6 O
% O
of O
patients O
randomized O
to O
the O
recommended O
doses O
( O
200 O
to O
400 O
mg/day O
) O
of O
VIMPAT O
( O
compared O
to O
2 O
% O
of O
placebo O
patients O
) O
. O

The O
onset O
of O
dizziness B-OSE_Labeled_AE
and O
ataxia B-OSE_Labeled_AE
was O
most O
commonly O
observed O
during O
titration O
. O

There O
was O
a O
substantial O
increase O
in O
these O
adverse O
events O
at O
doses O
higher O
than O
400 O
mg/day O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

5.3 O
Cardiac O
Rhythm O
and O
Conduction O
Abnormalities O
PR O
interval O
prolongation O
Dose-dependent O
prolongations B-OSE_Labeled_AE
in I-OSE_Labeled_AE
PR I-OSE_Labeled_AE
interval I-OSE_Labeled_AE
with O
VIMPAT O
have O
been O
observed O
in O
clinical O
studies O
in O
patients O
and O
in O
healthy O
volunteers O
[ O
see O
Clinical O
Pharmacology O
( O
12.2 O
) O
] O
. O

In O
adjunctive O
clinical O
trials O
in O
patients O
with O
partial B-Not_AE_Candidate
-onset O
epilepsy I-Not_AE_Candidate
, O
asymptomatic O
first B-OSE_Labeled_AE
- I-OSE_Labeled_AE
degree I-OSE_Labeled_AE
atrioventricular I-OSE_Labeled_AE
( O
AV O
) O
block I-OSE_Labeled_AE
was O
observed O
as O
an O
adverse O
reaction O
in O
0.4 O
% O
( O
4/944 O
) O
of O
patients O
randomized O
to O
receive O
VIMPAT O
and O
0 O
% O
( O
0/364 O
) O
of O
patients O
randomized O
to O
receive O
placebo O
. O

In O
clinical O
trials O
in O
patients O
with O
diabetic B-Not_AE_Candidate
neuropathy I-Not_AE_Candidate
, O
asymptomatic O
first B-OSE_Labeled_AE
- I-OSE_Labeled_AE
degree I-OSE_Labeled_AE
AV I-OSE_Labeled_AE
block I-OSE_Labeled_AE
was O
observed O
as O
an O
adverse O
reaction O
in O
0.5 O
% O
( O
5/1023 O
) O
of O
patients O
receiving O
VIMPAT O
and O
0 O
% O
( O
0/291 O
) O
of O
patients O
receiving O
placebo O
. O

Second B-OSE_Labeled_AE
degree I-OSE_Labeled_AE
and O
complete O
AV I-OSE_Labeled_AE
block I-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
in O
pain B-Not_AE_Candidate
studies O
and O
in O
patients O
with O
seizures B-Not_AE_Candidate
. O

When O
VIMPAT O
is O
given O
with O
other O
drugs O
that O
prolong B-NonOSE_AE
the I-NonOSE_AE
PR I-NonOSE_AE
interval I-NonOSE_AE
, O
further B-NonOSE_AE
PR I-NonOSE_AE
prolongation I-NonOSE_AE
is O
possible O
. O

VIMPAT O
should O
be O
used O
with O
caution O
in O
patients O
with O
known O
conduction O
problems O
( O
e.g. O
, O
marked O
first B-Not_AE_Candidate
- I-Not_AE_Candidate
degree I-Not_AE_Candidate
AV I-Not_AE_Candidate
block I-Not_AE_Candidate
, O
second B-Not_AE_Candidate
- I-Not_AE_Candidate
degree I-Not_AE_Candidate
or I-Not_AE_Candidate
higher I-Not_AE_Candidate
AV I-Not_AE_Candidate
block I-Not_AE_Candidate
and O
sick B-Not_AE_Candidate
sinus I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
without O
pacemaker O
) O
, O
sodium B-Not_AE_Candidate
channelopathies I-Not_AE_Candidate
( O
e.g. O
, O
Brugada B-Not_AE_Candidate
Syndrome I-Not_AE_Candidate
) O
, O
on O
concomitant O
medications O
that O
prolong B-NonOSE_AE
PR I-NonOSE_AE
interval I-NonOSE_AE
, O
or O
with O
severe O
cardiac B-Not_AE_Candidate
disease I-Not_AE_Candidate
such O
as O
myocardial B-Not_AE_Candidate
ischemia I-Not_AE_Candidate
or O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
or O
structural B-Not_AE_Candidate
heart I-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

In O
such O
patients O
, O
obtaining O
an O
ECG O
before O
beginning O
VIMPAT O
, O
and O
after O
VIMPAT O
is O
titrated O
to O
steady-state O
maintenance O
dose O
, O
is O
recommended O
. O

In O
addition O
, O
these O
patients O
should O
be O
closely O
monitored O
if O
they O
are O
administered O
VIMPAT O
through O
the O
intravenous O
route O
. O

One O
case O
of O
profound O
bradycardia B-OSE_Labeled_AE
was O
observed O
in O
a O
patient O
during O
a O
15-minute O
infusion O
of O
150 O
mg O
VIMPAT O
. O

There O
were O
two O
postmarketing O
reports O
of O
third B-NonOSE_AE
degree I-NonOSE_AE
AV I-NonOSE_AE
block I-NonOSE_AE
in O
patients O
with O
significant O
cardiac B-Not_AE_Candidate
history I-Not_AE_Candidate
and O
also O
receiving O
metoprolol O
and O
amlodipine O
during O
infusion O
of O
VIMPAT O
injection O
at O
doses O
higher O
than O
recommended O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
, O
Drug O
Interactions O
( O
7.2 O
) O
] O
. O

Atrial O
fibrillation O
and O
Atrial O
flutter O
In O
the O
short-term O
investigational O
trials O
of O
VIMPAT O
in O
epilepsy B-Not_AE_Candidate
patients O
, O
there O
were O
no O
cases O
of O
atrial B-NonOSE_AE
fibrillation I-NonOSE_AE
or O
flutter O
. O

Both O
atrial B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
and O
atrial B-OSE_Labeled_AE
flutter I-OSE_Labeled_AE
have O
been O
reported O
in O
open O
label O
epilepsy B-Not_AE_Candidate
trials O
and O
in O
postmarketing O
experience O
. O

In O
patients O
with O
diabetic B-Not_AE_Candidate
neuropathy I-Not_AE_Candidate
, O
0.5 O
% O
of O
patients O
treated O
with O
VIMPAT O
experienced O
an O
adverse O
reaction O
of O
atrial B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
or O
atrial B-OSE_Labeled_AE
flutter I-OSE_Labeled_AE
, O
compared O
to O
0 O
% O
of O
placebo-treated O
patients O
. O

VIMPAT O
administration O
may O
predispose O
to O
atrial B-OSE_Labeled_AE
arrhythmias I-OSE_Labeled_AE
( O
atrial B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
or O
flutter O
) O
, O
especially O
in O
patients O
with O
diabetic B-Not_AE_Candidate
neuropathy I-Not_AE_Candidate
and/or O
cardiovascular B-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

5.4 O
Syncope O
In O
the O
short-term O
controlled O
trials O
of O
VIMPAT O
in O
epilepsy O
patients O
with O
no O
significant O
system O
illnesses O
, O
there O
was O
no O
increase O
in O
syncope B-NonOSE_AE
compared O
to O
placebo O
. O

In O
the O
short-term O
controlled O
trials O
of O
VIMPAT O
in O
patients O
with O
diabetic B-Not_AE_Candidate
neuropathy I-Not_AE_Candidate
, O
1.2 O
% O
of O
patients O
who O
were O
treated O
with O
VIMPAT O
reported O
an O
adverse O
reaction O
of O
syncope B-OSE_Labeled_AE
or O
loss B-OSE_Labeled_AE
of I-OSE_Labeled_AE
consciousness I-OSE_Labeled_AE
, O
compared O
to O
0 O
% O
of O
placebo-treated O
patients O
with O
diabetic B-Not_AE_Candidate
neuropathy I-Not_AE_Candidate
. O

Most O
of O
the O
cases O
of O
syncope B-OSE_Labeled_AE
were O
observed O
in O
patients O
receiving O
doses O
above O
400 O
mg/day O
. O

The O
cause O
of O
syncope B-NonOSE_AE
was O
not O
determined O
in O
most O
cases O
. O

However O
, O
several O
were O
associated O
with O
either O
changes B-NonOSE_AE
in I-NonOSE_AE
orthostatic O
blood I-NonOSE_AE
pressure I-NonOSE_AE
, O
atrial B-NonOSE_AE
flutter/ O
fibrillation I-NonOSE_AE
( O
and O
associated O
tachycardia B-NonOSE_AE
) O
, O
or O
bradycardia B-OSE_Labeled_AE
. O

Cases O
of O
syncope B-OSE_Labeled_AE
have O
also O
been O
observed O
in O
open-label O
clinical O
epilepsy B-Not_AE_Candidate
studies O
. O

These O
cases O
were O
associated O
with O
a O
history O
of O
risk O
factors O
for O
cardiac B-Not_AE_Candidate
disease I-Not_AE_Candidate
and O
the O
use O
of O
drugs B-Not_AE_Candidate
that I-Not_AE_Candidate
slow I-Not_AE_Candidate
AV I-Not_AE_Candidate
conduction I-Not_AE_Candidate
. O

5.5 O
Withdrawal O
of O
Antiepileptic O
Drugs O
( O
AEDs O
) O
As O
with O
all O
AEDs O
, O
VIMPAT O
should O
be O
withdrawn O
gradually O
( O
over O
a O
minimum O
of O
1 O
week O
) O
to O
minimize O
the O
potential O
of O
increased B-NonOSE_AE
seizure I-NonOSE_AE
frequency I-NonOSE_AE
in O
patients O
with O
seizure B-Not_AE_Candidate
disorders I-Not_AE_Candidate
. O

5.6 O
Multiorgan O
Hypersensitivity O
Reactions O
One O
case O
of O
symptomatic O
hepatitis B-OSE_Labeled_AE
and O
nephritis B-OSE_Labeled_AE
was O
observed O
among O
4011 O
subjects O
exposed O
to O
VIMPAT O
during O
clinical O
development O
. O

The O
event O
occurred O
in O
a O
healthy O
volunteer O
, O
10 O
days O
after O
stopping O
VIMPAT O
treatment O
. O

The O
subject O
was O
not O
taking O
any O
concomitant O
medication O
and O
potential O
known O
viral B-NonOSE_AE
etiologies I-NonOSE_AE
for I-NonOSE_AE
hepatitis I-NonOSE_AE
were O
ruled I-NonOSE_AE
out I-NonOSE_AE
. O

The O
subject O
fully O
recovered O
within O
a O
month O
, O
without O
specific O
treatment O
. O

The O
case O
is O
consistent O
with O
a O
delayed O
multiorgan B-OSE_Labeled_AE
hypersensitivity I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
. O

Additional O
potential O
cases O
included O
2 O
with O
rash B-OSE_Labeled_AE
and O
elevated B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
enzymes I-OSE_Labeled_AE
and O
1 O
with O
myocarditis B-OSE_Labeled_AE
and O
hepatitis B-OSE_Labeled_AE
of O
uncertain O
etiology O
. O

Multiorgan B-OSE_Labeled_AE
hypersensitivity I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( I-OSE_Labeled_AE
also I-OSE_Labeled_AE
known I-OSE_Labeled_AE
as I-OSE_Labeled_AE
D I-OSE_Labeled_AE
rug I-OSE_Labeled_AE
R I-OSE_Labeled_AE
eaction I-OSE_Labeled_AE
with I-OSE_Labeled_AE
E I-OSE_Labeled_AE
osinophilia I-OSE_Labeled_AE
and I-OSE_Labeled_AE
S I-OSE_Labeled_AE
ystemic I-OSE_Labeled_AE
S I-OSE_Labeled_AE
ymptoms I-OSE_Labeled_AE
, I-OSE_Labeled_AE
or I-OSE_Labeled_AE
DRESS I-OSE_Labeled_AE
) O
have O
been O
reported O
with O
other O
antiepileptics O
and O
typically O
, O
although O
not O
exclusively O
, O
present O
with O
fever B-NonOSE_AE
and O
rash B-NonOSE_AE
associated O
with O
other O
organ O
system O
involvement O
, O
that O
may O
or O
may O
not O
include O
eosinophilia B-NonOSE_AE
, O
hepatitis B-NonOSE_AE
, O
nephritis B-NonOSE_AE
, O
lymphadenopathy B-NonOSE_AE
, O
and/or O
myocarditis B-NonOSE_AE
. O

Because O
this O
disorder O
is O
variable O
in O
its O
expression O
, O
other O
organ O
system O
signs O
and O
symptoms O
not O
noted O
here O
may O
occur O
. O

If O
this O
reaction O
is O
suspected O
, O
VIMPAT O
should O
be O
discontinued O
and O
alternative O
treatment O
started O
. O

5.7 O
Phenylketonurics O
VIMPAT O
oral O
solution O
contains O
aspartame O
, O
a O
source O
of O
phenylalanine O
. O

A O
200 O
mg O
dose O
of O
VIMPAT O
oral O
solution O
( O
equivalent O
to O
20 O
mL O
) O
contains O
0.32 O
mg O
of O
phenylalanine O
. O

